-
Impact of holoprosencephaly, exomphalos, megacystis and increased nuchal translucency on first-trimester screening for chromosomal abnormalities.
Syngelaki A, Guerra L, Ceccacci I, Efeturk T, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:45-48. pdf -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
The 11-13-week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis.
Kagan KO, Staboulidou I, Syngelaki A, Cruz JJ, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;36:10-4. -
Frontomaxillary facial angle at 11 + 0 to 13 + 6 weeks: effect of plane of acquisition.
Plasencia W, Dagklis T, Pachoumi C, Kolitsi E, Nicolaides KH.
Ultrasound Obstet Gynecol 2007;29:660-5. -
The mitral gap at 11 + 0 to 13 + 6 weeks: marker of trisomy 21 or artifact?
Maiz N, Dagklis T, Huggon I, Allan L, Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:813-8. -
Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection.
Lo YM, Tsui NB, Chiu RW, Lau TK, Leung TN, Heung MM, Gerovassili A, Jin Y, Nicolaides KH, Cantor CR, Ding C.
Nat Med 2007;13:218-23. -
Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13(+6) weeks of gestation.
Kagan KO, Frisova V, Nicolaides KH, Spencer K.
Prenat Diagn 2007;27:849-53. -
Ultrasound findings before amniocentesis in selecting the method of analysing the sample.
Kagan KO, Chitty LS, Cicero S, Eleftheriades M, Nicolaides KH.
Prenat Diagn 2007;27:34-9. -
Free fetal DNA in maternal circulation: a potential prognostic marker for chromosomal abnormalities?
Gerovassili A, Garner C, Nicolaides KH, Thein SL, Rees DC.
Prenat Diagn 2007;27:104-10. -
Nuchal translucency measurements for first-trimester screening: The 'price' of inaccuracy.
Evans MI, Van Decruyes H, Nicolaides KH.
Fetal Diagn Ther 2007;22:401-404. -
Frontomaxillary facial angle in chromosomally normal fetuses at 11 + 0 to 13 + 6 weeks.
Borenstein M, Persico N, Kaihura C, Sonek J, Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:737-41. -
The 11-14 week scan.
Nicolaides KH, Heath V, Liao AW.
Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:581-94. -
Pathophysiology of increased nuchal translucency in chromosomally abnormal fetuses.
von Kaisenberg CS, Brand-Saberi B, Jonat W, Nicolaides KH.
Der Gynäkologe 1999;32:193-199. -
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;13:231-7. -
International, collaborative assessment of 146,000 prenatal karyotypes: expected limitations if only chromosome-specific probes and fluorescent in-situ hybridization are used.
Evans MI, Henry GP, Miller WA, Bui TH, Snidjers RJ, Wapner RJ, Miny P, Johnson MP, Peakman D, Johnson A, Nicolaides K, Holzgreve W, Ebrahim SA, Babu R, Jackson L.
Hum Reprod 1999;14:1213-6. -
First trimester umbilical venous Doppler sonography in chromosomally normal and abnormal fetuses.
Brown RN, Di Luzio L, Gomes C, Nicolaides KH.
J Ultrasound Med 1999;18:543-6. -
Investigation of maternal blood enriched for fetal cells: role in screening and diagnosis of fetal trisomies.
Al-Mufti R, Hambley H, Farzaneh F, Nicolaides KH.
Am J Med Genet 1999;2;85:66-75. -
Screening for fetal abnormalities in multiple pregnancies.
Sebire NJ, Nicolaides KH.
Baillieres Clin Obstet Gynaecol 1998;12:19-36.